Pregabalin Capsule
Product Images NDC 70518-4481

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 70518-4481). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

This is a description of Pregabalin Capsule C-V in 25 mg quantity with 90 capsules. The capsules are white in color with the NDC number 70518-4481-00. The medication is manufactured by Ascend Labs, LLC, and repackaged by RemedyRepack Inc. It is important to keep this medication out of children's reach and store it at a temperature of 20-25°C. Additionally, there are instructions for permissible temperature excursions and reference to the USP standard.*

FDA Label Image

Pregabalin-equation (Pregabalin Equation)

This text includes information on calculating the creatinine clearance (CLCr) based on the age, weight, and serum creatinine level of a patient. The formula provided can be used for female patients with a CLCr greater than 0.85. The details on how to calculate the CLCr based on these parameters can be found in the text.*

FDA Label Image

Pregabalin-fig-a (Pregabalin Fig A)

This is a table showing the Responder Rate (%) for different dosage levels. The placebo had a rate of 2.5 mg/kg/day and 10 mg/kg/day. One of the values in the table is 201%.*

FDA Label Image

Pregabalin-figure-6 (Pregabalin Figure 6)

This text appears to show different studies comparing the effects of different dosages of a substance (possibly a medication) against a placebo. The text mentions percentages and results, indicating that the studies have found statistical significance in the comparison with the placebo for some dosages. The dosages tested include 50 mg/day, 150 mg/day, 300 mg/day, and 600 mg/day. The studies are denoted as "P Study E1" and "Study E3".*

FDA Label Image

Pregabalin-figure-7 (Pregabalin Figure 7)

FDA Label Image

Study Dpn 1 (Pregabalin Image 1)

FDA Label Image

Study Sci 1 (Pregabalin Image 10)

FDA Label Image

Pain Intensity-study Sci 2 (Pregabalin Image 11)

FDA Label Image

Study Dpn 2 (Pregabalin Image 2)

FDA Label Image

Study Phn 1 (Pregabalin Image 3)

FDA Label Image

Study Phn 2 (Pregabalin Image 4)

This text provides information about the improvement of patients after using different medications, including Pregabalin at different dosages and a placebo. It also mentions the percentage of improvement in pain compared to baseline.*

FDA Label Image

Study Phn 3 (Pregabalin Image 5)

The text shows data related to the percentage of patients improved using different treatments. It mentions Pregatalin taken a certain number of times per day, another variation of Pregatalin taken three times a day, and a placebo. The table also includes a graph indicating the percentage of improvement in pain from the baseline.*

FDA Label Image

Fibromyalgia Study F1 (Pregabalin Image 8)

This text provides information on the percentage of patients who showed improvement in pain after taking different doses of Pregabalin. It includes data for Pregabalin 100mg, 450mg, and 300mg daily doses. The text also mentions the improvement in pain measured as a percentage from the baseline. The table indicates the percentage of patients who experienced a certain level of pain improvement with different dosages of Pregabalin.*

FDA Label Image

Fibromyalgia Study F2 (Pregabalin Image 9)

FDA Label Image

Pregabalin Structure (Pregabalin Srtuc 1)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.